Why the study?
The study aimed to quantitatively evaluate literature data on the specific care of pregnant women with thrombophilia who are at risk of unplanned miscarriages.
This narrative review discusses the approach to screening and managing pregnant women with thrombophilia to mitigate the risk of unplanned miscarriages.
May inform thrombophilia screening in pregnancy; leaves open need for prospective trials to guide practice.
Thrombophilia is a genetic predisposition to hypercoagulable states caused by acquired haemostasis conditions; pregnancy causes the haemostatic system to become hypercoagulable, which grows throughout the pregnancy and peaks around delivery. Genetic testing for thrombophilic gene mutations is evaluated using different methodologies of real-time polymerase chain reaction and DNA microarrays of specific genes. Adapting the general care of the pregnant woman to the particularities caused by thrombophilia is an important component, so screening is preferred to assess the degree of genetic damage that manifests itself as a risk of thrombosis. The major goal of this narrative review was to quantitatively evaluate the literature data on the specific care of pregnant women with thrombophilia that are at risk of developing unplanned miscarriages.
No takes yet. Share an insight, caveat, or question.
Samfireag et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: